US 10,590,177 B2 · Modifications of cupredoxin derived peptides

Abstract

The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions elated to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.

Claims5

Dependent claims

A peptide which consists of the amino acid sequence:

(SEQ ID NO:
49)
DDPKLYDKDLGSA X1X2 D X3 VV X4 X5 X6 DAA X7 SL;
wherein the N terminus may or may not be acetylated;
wherein X1 is selected from the group consisting of M, L and V;
wherein X2 is selected from the group consisting of G, T and W;
wherein X3 is selected from the group consisting of T and W;
wherein X4 is selected from the group consisting of G and A;
wherein X5 is selected from the group consisting of Q and W;
wherein X6 is selected from the group consisting of M, L and V;
wherein X7 is selected from the group consisting of T and W;
and
wherein the C terminus may or may not be amidated.

10 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/969,920Filed 3 May 2018 · division

Priority

7 Oct 2004

Published

US 2018/0319848 A18 Nov 2018

Granted

17 Mar 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 14/21
From bacteria: from Pseudomonadaceae
A61K 38/04
Medicinal preparations containing peptides: peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids
A61K 38/10
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 12 to 20 amino acids

Family

Application60/616,782Us provisional application · filed 7 Oct 2004

Application60/680,500Us provisional application · filed 13 May 2005

Application11/244,105Parent of this continuation-in-part · filed 6 Oct 2005

Application60/843,388Us provisional application · filed 11 Sep 2006

Application11/853,497Parent of this division · filed 11 Sep 2007

US 2018/0319848 A1Pre-grant publication · published 8 Nov 2018

US 10,005,821 B2Parent of this division

US 7,691,383 B2Parent of this continuation-in-part

Application11/853,497Parent of this continuation-in-part

US 2006/0149037 A1Published application

US 2010/0267608 A1Published application

US 10,590,177 B2This patent

From the US filing history. Foreign family members aren’t listed.

Modifications of cupredoxin derived peptides

Life of this patent

Modifications of cupredoxin derived peptides

Life of this patent

Abstract

Claims5